Kuo-liang T. Wei

Taoyuan, TNQ 33302, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Correction: Chang et al. Inhibition of CCAR1, a Coactivator of β-Catenin, Suppresses the Proliferation and Migration of Gastric Cancer Cells. Int. J. Mol. Sci. 2017, 18, 460.

Correction: Chang et al. Inhibition of CCAR1, a Coactivator of β-Catenin, Suppresses the Proliferation and Migration of Gastric Cancer Cells. Int. J. Mol. Sci. 2017, 18, 460.

Journal: International journal of molecular sciences

Published: May 12, 2026

PKF118-310 as a Potential Small Molecule Inhibitor Targeting the Wnt/β-Catenin Pathway for Gastric Cancer Therapy.

PKF118-310 as a Potential Small Molecule Inhibitor Targeting the Wnt/β-Catenin Pathway for Gastric Cancer Therapy.

Journal: Anticancer research

Published: August 10, 2025

Dexlansoprazole is an aryl hydrocarbon receptor agonist.

Dexlansoprazole is an aryl hydrocarbon receptor agonist.

Journal: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association

Published: October 01, 2024

Immunological hide-and-seek: epigenetically reprogrammed cancer cells and the dynamics of CD8+ T cells.

Immunological hide-and-seek: epigenetically reprogrammed cancer cells and the dynamics of CD8+ T cells.

Journal: Molecular biology reports

Published: June 13, 2024

Weight Gain and Increased Body Mass Index in Patients with Hepatitis C after Eradication Using Direct-Acting Antiviral Therapy in Taiwan.

Weight Gain and Increased Body Mass Index in Patients with Hepatitis C after Eradication Using Direct-Acting Antiviral Therapy in Taiwan.

Journal: Diagnostics (Basel, Switzerland)

Published: December 17, 2023

Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy.

Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy.

Journal: Diagnostics (Basel, Switzerland)

Published: December 25, 2022

Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis.

Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis.

Journal: Viruses

Published: November 19, 2022

Sorafenib is an antagonist of the aryl hydrocarbon receptor.

Sorafenib is an antagonist of the aryl hydrocarbon receptor.

Journal: Toxicology

Published: July 16, 2021

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.

Journal: BMC gastroenterology

Published: April 19, 2021

Fusobacterium nucleatum colonization is associated with decreased survival of helicobacter pylori-positive gastric cancer patients.

Fusobacterium nucleatum colonization is associated with decreased survival of helicobacter pylori-positive gastric cancer patients.

Journal: World journal of gastroenterology

Published: April 11, 2021

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.

Journal: Scientific reports

Published: March 26, 2021

Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.

Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.

Journal: Journal of gastroenterology and hepatology

Published: March 09, 2021

Showing 1-12 of 35

Last Updated: 09/26/2026